Clinical trial with a novel cancer vaccine strategy in malignant lymphoma
- Prosjektnummer
- 2016068
- Ansvarlig person
- Arne Kolstad
- Institusjon
- Oslo universitetssykehus HF
- Prosjektkategori
- Postdoktorstipend
- Helsekategori
- Cancer
- Forskningsaktivitet
- 5. Treatment Developement
Nei
Nei
NEI
Nei
Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk.
BMC Cancer 2020 Dec 07;20(1):1202. Epub 2020 des 7
PMID: 33287742
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of
Eur J Nucl Med Mol Imaging 2021 06;48(6):1902-1914. Epub 2020 nov 16
PMID: 33196921
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
Blood Adv 2020 Sep 08;4(17):4091-4101.
PMID: 32877524
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.
Br J Haematol 2020 Aug 04. Epub 2020 aug 4
PMID: 32748433
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003.
PLoS One 2020;15(3):e0230526. Epub 2020 mar 18
PMID: 32187209
Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL.
Blood 2020 May 28;135(22):2000-2004.
PMID: 32181815
mutations and
Haematologica 2020 Jun;105(6):1604-1612. Epub 2019 sep 19
PMID: 31537689
Finding Neo (antigens, that is).
Blood 2019 07 11;134(2):108-109.
PMID: 31296544
Induction of neoantigen-reactive T cells from healthy donors.
Nat Protoc 2019 06;14(6):1926-1943. Epub 2019 mai 17
PMID: 31101906
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate
Eur J Nucl Med Mol Imaging 2019 Oct;46(11):2311-2321. Epub 2019 jul 15
PMID: 31309259
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.
Blood Adv 2019 04 23;3(8):1230-1243.
PMID: 30979721
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.
Cancer Immunol Res 2019 03;7(3):355-362. Epub 2019 jan 18
PMID: 30659053
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.
Br J Haematol 2018 Oct;183(2):225-234. Epub 2018 aug 6
PMID: 30080252
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of
Haematologica 2018 Nov;103(11):e541-e543. Epub 2018 mai 24
PMID: 29794145
Pre-dosing with lilotomab prior to therapy with
Eur J Nucl Med Mol Imaging 2018 07;45(7):1233-1241. Epub 2018 feb 22
PMID: 29470615
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Lancet Haematol 2018 Mar;5(3):e109-e116. Epub 2018 jan 29
PMID: 29396091
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
Clin Cancer Res 2018 Feb 15;24(4):870-881. Epub 2017 des 7
PMID: 29217528
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate
J Nucl Med 2018 Apr;59(4):704-710. Epub 2017 aug 28
PMID: 28848035
Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years.
Hematol Oncol 2018 Feb;36(1):217-223. Epub 2017 apr 9
PMID: 28393375
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
Cancer Immunol Res 2018 04;6(4):467-480. Epub 2018 feb 19
PMID: 29459477
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
Blood 2017 10 26;130(17):1903-1910. Epub 2017 aug 17
PMID: 28819011
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Biol Blood Marrow Transplant 2017 Mar;23(3):428-435. Epub 2016 des 27
PMID: 28039078
Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma.
Leuk Lymphoma 2017 Mar;58(3):623-632. Epub 2016 jul 7
PMID: 27389974
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Blood 2017 02 09;129(6):759-770. Epub 2016 des 23
PMID: 28011673
Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations.
Cytometry B Clin Cytom 2017 Jan;92(1):79-87.
PMID: 27933753
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.
J Nucl Med 2017 Jan;58(1):55-61. Epub 2016 sep 1
PMID: 27587710
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.
J Nucl Med 2017 Jan;58(1):48-54. Epub 2016 aug 4
PMID: 27493270
The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy.
Front Immunol 2017;8():1718. Epub 2017 des 11
PMID: 29321773
Defective IL-4 signaling in T cells defines severe common variable immunodeficiency.
J Autoimmun 2017 Jul;81():110-119. Epub 2017 mai 3
PMID: 28476239
Manufacture of CAR-T cells in the body.
Nat Biotechnol 2017 Jun 07;35(6):520-521.
PMID: 28591119
Patterns of constitutively phosphorylated kinases in B cells are associated with disease severity in common variable immunodeficiency.
Clin Immunol 2017 Feb;175():69-74. Epub 2016 des 3
PMID: 27919819
Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease.
J Hepatol 2017 Jan;66(1):116-122. Epub 2016 sep 17
PMID: 27647428
- Maarja Laos Postdoktorstipendiat (finansiert av denne bevilgning)
- Johanna Olweus Forskningsgruppeleder
- Amit Mandoli Postdoktorstipendiat (finansiert av denne bevilgning)
- Arne Kolstad Prosjektleder
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport